
|Videos|April 21, 2014
Sequencing New Agents in Prostate Cancer
Author(s)James Mohler, MD
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.
Advertisement
Clinical Pearls
James Mohler, MD, chair, Department of Urology, associate director, Translational Research, Roswell Park Cancer Institute, discusses sequencing agents in prostate cancer.
- The FDA has approved 5 agents in the last 5 years, each of which extend survival by 2-5 months in patients with prostate cancer
- There remains a need to determine the appropriate sequencing of these agents
- Research is being conducted to develop a biomarker of response to hormonal therapy
- Research is being conducted in mouse models to reach an answer quickly, rather than wait for a clinical trial
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































